Evidence map›Paper›PMID 40679371›Full record

ArticleRadiology. Imaging cancer2025

Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.

Maya Gilad, Savannah C Partridge, Mami Iima, Rebecca Rakow-Penner Md, Moti Freiman

Registry-linked trialAbstract readDataset
In one paragraph

Article in Radiology. Imaging cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01042379 (I-SPY Trial), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01042379 phase2recruitingnot on this map

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

TypeinterventionalSponsorQuantumLeap Healthcare CollaborativeRan2010 to 2031Enrolled5,000ConditionsBreast Neoplasms, Breast Cancer, Breast Tumors, AngiosarcomaArmsStandard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Monitoring Pharmacological Treatment of Breast Cancer with MRI.Current issues in molecular biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maya GiladFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.ORCID 0000-0002-3869-5165
Savannah C PartridgeDepartment of Radiology, University of Washington School of Medicine, Seattle, Wash.ORCID 0000-0001-6370-9111
Mami IimaDepartment of Fundamental Development for Advanced Low Invasive Diagnostic Imaging, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-1991-2494
Rebecca Rakow-Penner MdDepartment of Radiology, University of California San Diego, La Jolla, Calif.ORCID 0000-0002-2566-1978
Moti FreimanFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.ORCID 0000-0003-1083-1548

Funding

Elimination of Instrumental Bias for Quantitative Diffusion Imaging in Clinical Oncology TrialsR01CA190299 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MALYARENKO, DARIYA I. · 2015 to 2025
$6.4M
Validation and Standardization of the Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker in Breast CancerR01CA207290 · NCI · UNIVERSITY OF WASHINGTON · PI PARTRIDGE, SAVANNAH CORRINA · 2017 to 2022
$2.2M
NCI NIH HHS R01 CA190299NCI NIH HHS R01 CA207290
6 · The paper itself

Abstract

Purpose To evaluate the performance of a machine learning model developed using radiomics data derived from physiologically decomposed diffusion-weighted MRI data for predicting pathologic complete response (pCR) following neoadjuvant chemotherapy for breast cancer compared with baseline and benchmark models. Materials and Methods This retrospective study included data from the Breast Multiparametric MRI for prediction of neoadjuvant chemotherapy Response (BMMR2) challenge dataset, comprising longitudinal multiparametric breast MRI studies (diffusion-weighted imaging [DWI] and dynamic contrast-enhanced MRI) from participants enrolled in the I-SPY 2/ACRIN 6698 trial (ClinicalTrials.gov: NCT01042379). Piecewise linear physiologic decomposition was applied to DWI data (PD DWI) to isolate pseudo-diffusion, pure-diffusion, and pseudo-diffusion fraction components for radiomics feature extraction. These features were used to develop a boosted decision tree model to predict pCR following neoadjuvant chemotherapy. Model performance was compared with performance of baseline models, including data on tumor size and mean apparent diffusion coefficient, and the BMMR2 challenge benchmark model using area under the receiver operating characteristic curve, F1 score, and positive and negative predictive values. Model calibration was assessed via the Brier score, and a decision curve analysis was performed to estimate the potential reduction in unnecessary interventions when using the proposed model. Results The study included multiparametric MRI scans from 190 female participants (mean age ± SD, 48.4 years ± 10.5). PD DWI achieved the highest area under the receiver operating characteristic curve (0.89, 95% CI: 0.81, 0.96) among all evaluated models, demonstrating statistically significant improvements over baseline approaches (all

Indexed as

Breast NeoplasmsDiffusion Magnetic Resonance ImagingMachine LearningNeoadjuvant TherapyAdultBreastChemotherapy, AdjuvantFemaleHumansMiddle AgedMulticenter Studies as TopicPredictive Value of TestsRadiomicsRetrospective StudiesTreatment OutcomeBreastExperimental InvestigationsImage PostprocessingMR-Diffusion Weighted ImagingTumor Response

Identifiers

PMID40679371
PMCPMC12304534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.